Marker Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview

Marker Therapeutics

09/05/2025 12:13

Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to show a fall in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025

The Houston Texas-based  company is expected to report a 59.8% decrease in revenue to $500 thousand from $1.24 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 21.3% in the last three months. ​

Wall Street's median 12-month price target for Marker Therapeutics Inc is $10.25​, above​ its last closing price of $1.28. ​​​

This summary was machine generated May 9 at 11:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)